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The progress that has occurred in medicine during our life-
times has been unparalleled . Forty years ago, rheumatic fever
was widespread, mitral valvulotomy had not been success-
fully performed, the heart-lung machine had not been applied
to humans and intensive care meant that the
physician sat at the patient's bedside . Today,
rheumatic fever has been all but eliminated, val-
vular heart surgery is commonplace with an op-
erative mortality of <4%, the heart-lung machine
is used in over one quarter of a million patients
each year and our intensive care units, with their
sophisticated monitoring apparatus, are show-
places of modern technology as applied to medi-
cine. Although day to day progress by medical
scientists occurred slowly, the overall effect produced by our
unique blend of academic medicine, industry and the practi-
tioner has resulted in a level of progress that no Solomon
could have predicted .
Advances in cardiac surgery have occurred through so
many routes that future directions are very difficult to
predict. The dedicated clinician-scientist tackles a recog-
nized problem, a surgeon changes the format of an opera-
tion, an industrial laboratory focuses money and personnel ;
each approach appears to have an even chance of advancing
our field . The most we can accomplish in our review is to
indicate areas in which research effort is being expended and
areas in which advances in our abilities would have a
favorable impact on patient care .
Vascular Surgery
Prosthetic grafts. The recognition that inert fabric tubes
could serve as blood vessel substitutes provided a range of
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therapeutic options for patients with vascular disease (1) .
The use of prosthetic grafts evolved along with the specialty
of vascular surgery . Modifications to encourage uniform
tissue ingrowth, low initial porosity and external supports to
prevent buckling have been secondary improve-
ments that have been readily incorporated into
clinical surgery .
When fabric grafts are used in vessel sizes of
<I 0 mm in diameter the patency rate decreases
to unacceptable values when compared with the
rate obtained with the use of the reversed autog-
enous saphenous vein. A variety of treated
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biologic vessels have been used but, thus far,
Initial enthusiasm has been counteracted by pre-
mature degeneration . The development of microporous
polytetrafluorethylene (PTFE) grafts has resulted in an off
the shelf prosthesis that provides acceptable results in the 6
to 10 mm range when autogenous vein is not available or its
use is inadvisable ( ) .
The need for a small vessel prosthesis (<6 mm in diam-
eter) has been recognized for > decades. Although there is
no shortage of scientific articles indicating the accomplish-
ment of this task, no small vessel prosthesis is available
when a graft is required for a specific clinical application
(3-4) . Despite the general recognition that the availability of
a small vessel prosthesis would have a major clinical impact
and that fortunes are to be made from the development of
such a graft, no satisfactory prosthesis is forthcoming . A
better understanding of the phenomena that occur at the
anastomotic sites, new knowledge regarding the relative
advantages and disadvantages of a porous versus a non-
This article is part of a series of articles celebrating the
40th anniversary of the American College of Cardiology .
The series attempts to set the stage for the future by
describing current state of the art management of selected
major cardiovascular problems and the basic knowledge
that will provide directions for advances in diagnosis and
therapy .
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porous prosthesis wall and, possibly, improved materials
will play a role in this development . Although the saphenous
vein is a "friend" of the vascular surgeon, there are many
instances in which it is not available or should be left
alone, an autogenous artery is not sufficient and a com-
mercial prosthesis, sized for the task at hand, should be
used .
Techniques for blood vessel anastomosis . The potential
usefulness of rapid techniques for blood vessel anastomoses
have been recognized for decades . The Soviet blood vessel
stapling device rekindled an interest in non-suture tech-
niques (5). Vascular staplers work satisfactorily if there is
reasonable access to the vessels, adequate cuff lengths and
minimal atherosclerosis . When these criteria are not met,
most surgeons find it quicker to perform a conventional
suture anastomosis. However, the successful application of
the sutureless blood vessel connector has been very helpful
in simplifying the repair of aneurysms of the thoracic aorta
(6) . Similar techniques will be applied to other blood vessels
with advantage . Other options of rapid blood vessel anasto-
moses that have promise include the use of tissue adhesives
and laser welding (7,8) .
Laser techniques . The availability of laser techniques will
increase the therapeutic options in vascular surgery (8) .
Laser angioscopy will allow visualization of stenotic lesions
and will permit the surgeon to decide on the pros and cons of
angioplasty techniques (dilation versus laser ablation) versus
direct surgical approaches . Blind vascular procedures will
no longer be performed . Moreover, for vessels in which
direct dilation is the treatment of choice, but in which
restenosis is a distinct possibility, a thin-walled, mesh type,
metal stent will be inserted intravascularly to obviate this
possibility (9) .
Cardiopulmonary Bypass
Heparin anticoagulation . The availability of heparin was
crucial to the development of the heart-lung machine . Com-
mercial heparin remains a complex biologic chemical, ex-
tracted from slaughterhouse animals and composed of a
mixture of mucopolysaccharides of varying anticoagulant . A
single compound having uniform activity, no antigenicity
and no effect on platelets will improve our ability to
achieve anticoagulation during cardiopulmonary bypass
and then completely reverse the effect of the drug (10) . Of
possibly greater importance will be the availability of a
heparin antagonist that does not have the allergenic effects
or the cardiovascular effects of biologically derived prota-
mine (11) .
Modern membrane oxygenators without heparin . The
ability to perform cardiopulmonary bypass without heparin
would simplify certain open heart operations, decrease op-
erating time and reduce blood loss and transfusion require-
ments. At present, the thoracic aorta can be bypassed with
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use of left atrial to aortic pumping without heparin (1 ) . Shed
blood is heparinized as it is sucked from the operative field .
The advantages of such a system are clear. The major
element in a pump oxygenator, in which clotting occurs if
inadequate heparin is present, is the oxygenator . Modern
membrane oxygenators are now making their mark in car-
diac surgery ; their modification to prevent activation of
coagulation without the use of systemic heparin will repre-
sent another major advance .
Agents to prevent platelet sequestration and activation .
Platelets are sequestered in the liver during cardiopul-
monary bypass and those that are available after bypass
may not be capable of participating in the formation of
platelet plugs . Congeners of prostacycline are now being
studied that may significantly reduce sequestration and
activation of the platelet during cardiopulmonary bypass
(13) . Again, the appropriate use of such pharmacologic
agents will result in the reestablishment of normal coagula-
tion mechanisms immediately after the completion of cardio-
pulmonary bypass .
Percutaneous cardiopulmonary bypass. The availability
of percutaneous techniques to initiate cardiopulmonary by-
pass will mean that such bypass will be used to advantage as
a resuscitation tool, with strict guidelines regarding indica-
tions for use, and as a circulatory support tool for patients
undergoing intracardiac (valvular) or coronary artery manip-
ulation (14,15). In the emergency situation, the benefit of the
prompt institution of percutaneous cardiopulmonary support
will be as apparent as are the advantages of the percutaneous
intraaortic balloon .
Congenital Heart Disease
Advances in membrane oxygenation, myocardial protec-
tion and ventricular assist pumps . Over the past decades,
the thrust toward primary definitive repair early in life has
required increasing sophistication in anesthetic manage-
ment, cardiopulmonary bypass and circulatory arrest tech-
niques and postoperative intensive care . Further advances
with more efficient membrane oxygenation requiring smaller
priming volume are still needed and are currently in devel-
opment . Myocardial protection in the neonate has been
shown to be quite different from that in the mature myocar-
dium (16) . Although basically more resistant to ischemia,
neonatal myocardium is not protected by multidose car-
dioplegia with use of St . Thomas Hospital solution as is the
adult heart (17) . This metabolic riddle, possibly related to
calcium flux, will be resolved, providing improved myocar-
dial protection allowing longer aortic cross-clamp times and
thus more time for intracardiac repair of complex defects .
The use of extracorporeal membrane oxygenation for com-
plete cardiopulmonary support has been successful in neo-
nates with reversible lung disease and in pediatric patients
with acute cardiorespiratory failure after repair of cardiac
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defects (18) . Ventricular assist pumps for infants and chil-
dren are under development and should be ready for clinical
trials within the next years. This pump will be of great
benefit not only in the management of postoperative low
cardiac output but as a bridge to transplantation in infants
requiring cardiac substitution . These ventricular assist
pumps may also be of immense help in the management of
postoperative right ventricular failure so common after re-
pair of congenital cardiac lesions .
Tetralogy of Fallot repair . Although some advocate com-
plete repair of tetralogy of Fallot in neonates (19), most
recommend a modified Blalock-Taussig shunt in the first 6
months of life in view of the higher mortality for the single
stage approach ( 0) . With surgical experience, improved
cardiopulmonary bypass and other support techniques, neo-
natal repair will become more universal .
The arterial switch operation for transposition of the great
arteries in neonates . This operation has shown great promise
and the operative mortality has continued to decrease ( 1) .
Shortly, the mortality rate will undoubtedly fall to the to
3% level now associated with the overall less satisfactory
atrial redirection operation, which in long-term follow-up
has been associated with arrhythmia and right ventricular
dysfunction .
Atrioventricular septal defects and pulmonary hyperten-
sion . Results of operations for complete atrioventricular
septal defect have vastly improved as we have gained a
better understanding of the cardiac anatomy of this com-
plex defect ( ) . Further understanding of the complexities
of the pathophysiology of pulmonary hypertension in these
babies is, however, required to master the problems associ-
ated with repair of atrioventricular septal defects and other
intracardiac lesions . Repair earlier in infancy eliminates
some of the problems with long-standing pulmonary artery
hypertension. In addition, improved ventilators and drugs
specifically acting on the pulmonary circulation will be
developed .
Tricuspid atresia and univentricular and hypoplastic heart
syndrome . The dramatic results achieved with the modified
Fontan procedure now allow not only excellent palliation
in tricuspid atresia but many other complex lesions
such as univentricle (double inlet right ventricle, double
inlet left ventricle) heterotaxy syndrome and even the
hypoplastic left heart syndrome ( 3) . Further refinements
in preoperative assessment, surgical techniques and sup-
port systems will enhance the results in the repair of these
lesions ( 4- 7) .
The argument for cardiac transplantation in the hypoplas-
tic left heart syndrome is a persuasive one : 19 of infants
have survived ( 8) . However, the lack of donors and the high
attrition rate of these infants while awaiting a suitable donor
result in a final overall outcome not unlike that for the two
stage Norwood procedure ( 9) .
PIERCE ET AL .
	
67
CARDIAC SURGERY: FUTURE
Coarctation of the aorta . Repair of coarctation of the
aorta in the future will be done during the 1st year of life
even in asymptomatic infants to avoid the serious late
sequelae so common after repair in older children . The use
of absorbable sutures and the subclavian flap procedure in
infants provide immediate postoperative results almost com-
parable with those in older children (30,31) . Further refine-
ment in techniques will eliminate the small number of
recurrences (3%) . Repair of the associated intracardiac
defects has been a major challenge but, as the repair of
these defects without coarctation improves, a similar im-
provement will be seen when they are associated with
coarctation .
Interrupted aortic arch remains a challenge . Better sup-
port techniques will make a one stage repair of the arch,
as well as closure of the ventricular septal defect, the
operation of choice with good immediate and long-term
results (3 ) .
Therefore, the number of congenital cardiac lesions not
amenable to operative repair has rapidly declined to a point
where almost all lesions can be either repaired or palliated .
The future will bring greatly improved immediate and long-
term results .
Cardiac Valve Prostheses
Mechanical versus biologic prosthesis . The first cardiac
valve to be successfully implanted in a patient was of the
ball-in-cage type (33) . Valves of this type, albeit with minor
but important changes, are being used today as state-
of-the-art mechanical prostheses . Several types of tilting
disc valves which have certain advantages over the ball-
in-cage prosthesis, are also available . In some valves, inert,
highly polished pyrolytic carbon has replaced inert, highly
polished metal . All mechanical valves now available have
excellent durability, but the patients require continuous
anticoagulant therapy with warfarin to minimize throm-
boembolism . The balance between bleeding and thrombus
formation is a delicate one and requires periodic prothrom-
bin time determinations for the life of the patient . The use of
glutaraldehyde-fixed biologic valves brought the hope that
the incidence of valve-related thromboembolism would be
reduced and that, at least in certain instances, anticoagulant
therapy would no longer be required . As these hopes have
materialized, gradual, progressive valve degeneration has
occurred (34) . Deterioration results in a need to replace a
bioprosthesis, frequently in elderly patients, and has led
surgeons to reevaluate their use of fixed tissue valves .
Accordingly the pendulum is currently swinging toward the
use of mechanical prosthetic valves in most patients, even
those into their 70s, a group for whom tissue valves were
previously reserved .
Unfortunately, research activity to develop improved
heart valves in the United States has declined to new
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lows because of a scarcity of really good, new ideas, the
tremendous costs, the long time frame associated with
obtaining Food and Drug Administration approval and
concern for the potential liability associated with any mal-
occurrence .
Aortic valve homografts . The use of stored aortic valve
homografts has offered some hope and, if reported results
indicating good, long-functioning life are confirmed, many
more of these valves will be used in the future in the aortic
location (35) . The logistics of obtaining sterile cadaver
valves and the additional complexity of insertion mean that
the homograft valve will not qualify as the elusive ideal
valvular prosthesis .
Polyurethane trileaflet valve prosthesis . Manufactured
frame-mounted trileaflet valves have many desirable fea-
tures, but the material design combinations evaluated thus
far have not resulted in a clinically useful prosthesis
(36,37) . It is hoped that a better understanding of the valve
mechanics, improved design using sewing rings that
become incorporated into the valve annulus and the use of
thin, inert, flexible polymer leaflets will result in a manu-
factured valve, suitable for any location, that does not
require anticoagulant therapy and has a functional lifetime
measured in decades .
Coronary Artery Surgery
Internal mammary artery versus saphenous vein grafts .
Few areas in contemporary medicine have been the sub-
ject of as much debate as the role of surgery in the treat-
ment of coronary artery disease . As coronary artery
surgery enters its 3rd decade, there continues to be more
frequent use of both internal mammary arteries, thereby
reducing the need to use the saphenous vein for coronary
artery grafting (38,39) . The superior long-term patency of
the internal mammary artery when compared with saphe-
nous vein graft will provide improved survival, reduced
cardiac-related morbidity and a decreased need for reoper-
ation (40-4 ) .
Changing characteristics of surgical candidates . Unfortu-
nately, operative mortality and morbidity rates for coronary
artery bypass grafting are likely to increase . This increase is
and will be related to major changes in the baseline charac-
teristics of patients undergoing the operation . Clearly, the
surgical population will continue to consist of a subset with
a high incidence of advanced age, severe coronary artery
disease, left ventricular dysfunction and multiple concomi-
tant medical problems (43) . Additionally, urgent procedures
will probably continue to increase in frequency, in many
cases after other therapeutic interventions, such as throm-
bolysis and percutaneous transluminal angioplasty have
been performed (44-47). In contrast, exciting new develop-
ments in myocardial protection and salvage and the use of
devices designed for intra-arterial application will help the
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surgeon improve the aspects of coronary artery surgery not
related to the surgeon's patient selection . This future use of
improved myocardial protection and high technology, in-
cluding lasers and angioscopes, may allow the surgeon to
deal more effectively with severe, diffuse coronary artery
disease and with patients who have impaired ventricular
function .
Coronary angioscopy . Direct visual examination of the
interior surface of intact human coronary arteries is now a
reality (48,49). Certainly, it will prove to be a valuable
research application in characterizing the atherosclerotic
process . However, the most important future surgical
application lies in its potential use as an adjunct to intra-
operative angioplasty, thus allowing more suitable revas-
cularization in patients with diffuse coronary artery
disease. Additionally, technical anastomotic misadventures
may be visualized and corrected, leading to improved graft
patency (50) .
Laser ablation of atherosclerotic plaques . Manual coro-
nary endarterectomy to deal with diffuse coronary artery
disease has not gained widespread acceptance in the United
States because its safety and durability have been ques-
tioned (51) . The laser can vaporize calcific plaques in a
partially or totally obstructed artery making it a potentially
useful tool to treat totally occluded as well as diffusely
narrowed vessels (5 ) . Apparently, laser surgery of normal
and atherosclerotic arteries results in a scar that heals
quickly with a new endothelial covering (53) . For laser
systems to become useful for ablation of atherosclerotic
plaque . they must have little effect on normal tissue to
minimize risk of perforation . At present "hot tip" (argon or
YAG), excimer or "cold" and carbon dioxide lasers are
under investigation . With each, the investigator must find
the proper power and time of exposure to allow selective
ablation without perforation or damage to normal structures .
Advances and development of exogenous chromophores to
detect fluorescent plaque will enable the laser system to
spectroscopically recognize and distinguish atheroma and
normal arterial wall and may assist in preventing perforation
or vessel damage (54,55) .
In the operating room, open laser endarterectomy may
provide precise control over the plane of dissection . Heat
sealing the surface and end points of dissection may be a
potential improvement over the conventional manual surgi-
cal techniques (56) . Eventually, these techniques may be
possible percutaneously . Laser welding of small vessel anas-
tomoses in which low-laser energy is applied to opposed
vessel edges may prove quicker and superior to conventional
suturing techniques (57) . These anastomoses show no suture
foreign body reaction, and neointimal hyperplasia may be
reduced (58) . These characteristics may enhance the patency
of these small vessel anastomoses .
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Myocardial Protection and Salvage
Newer techniques to preserve myocardial structure and
prevent ischemic damage . The quest for the optimal alchemy
of cardioplegic solutions will continue . As the mechanism of
reperfusion injury is unlocked, appropriate pharmacologic
additives will scavenge or inhibit production of oxygen free
radicals, block intracellular calcium influx, favorably change
the balance between prostacyclin and thromboxane and
inhibit lipolysis to afford additional myocardial protection
and limit ischemic damage (59) . Other changes in the com-
position of the reperfusate in an effort to provide substrate
for adenosine triphosphate (ATP) production may prove
pivotal in preserving myocardial structure and function after
periods of ischemia (60) . Further insights into the conditions
of reperfusion are certain to evolve as laboratory findings,
indicating the critical importance of decompressing the left
ventricle and gentle reperfusion . are applied in clinical trials
and compared with current techniques of thrombolytic ther-
apy with or without angioplasty in the acute setting of
ischemia (61,6 ) .
Retrograde coronary sinus infusion . Obviously, myocar-
dial protection cannot be separated from its methodology .
The role of retrograde infusion of cardioplegia through
the coronary sinus as well as other coronary sinus inter-
ventions will unravel (63,64) . This complex area of myocar-
dial protection will continue to be an area of fruitful inves-
tigation, and certainly methodology first applied in the
operating room will be found useful in the percutaneous
route to assist the invasive cardiologist in certain acute
ischemic settings .
Arrhythmia Surgery
Cardiac pacemakers. More than 50 years ago, an artificial
external pacemaker and bipolar leads were designed and
used successfully in patients . From these crude beginnings,
change in the field of cardiac stimulation has been so rapid
that the future becomes the past . Soon, most pacemakers
will be dual chamber devices as small as, if not smaller than,
present day single chamber units and will have similar
longevity and programmable features . A single implantable
unit will have a multiplicity of antitachycardia modes and
even permit automatic defibrillation . It is conceivable
that units designed for defibrillation will no longer require
thoracotomy for defibrillator lead placement (65) . Physio-
logic sensors will be developed to permit autoregulation
of the pacemaker to maintain optimal hemodynamics .
Transtelephonic monitoring systems will be developed to
fully interrogate and even reprogram devices . These pace-
makers will be capable of data acquisition and storage and
allow serial electrophysiologic testing to assess a given
therapeutic regimen (66) . The technologic advances in this
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area appear limited only by our investigative and capital
resources .
Direct arrhythmia surgery . Such surgery is now entering
its 3rd decade and is well established for certain patients
with refractory supraventricular and ventricular arrhyth-
mias. Surgical division of accessory pathways in the Wolff-
Parkinson-White syndrome is associated with minimal risk
and excellent results (67) . Clinical trials in the future will
define the superiority or equality of endocardial versus
epicardial closed heart approaches .
Supraventricular tachyarrhythmias . Although atrioven-
tricular (AV) node reentrant tachycardia has been ap-
proached in a variety of ways, most entailed His bundle
ablation coupled with permanent pacer implantation .
Recent experience (68) indicates that this syndrome may be
effectively treated by discrete cryosurgical lesions placed
about the borders of the AV node . Future clinical experience
may allow a closed heart technique and ultimately even a
percutaneous technique . Although computerized mapping
techniques are not necessary to obtain optimal results in
the previously discussed conditions, mapping originally
developed for use in ventricular tachycardia surgery
may allow detailed electrophysiologic study of the atrium
during automatic atrial tachycardias as well as atrial
fibrillation and flutter. If the arrhythmia can be mapped,
then a surgical technique to ablate it can be developed .
Already, left and right atrial isolation procedures as well as
local procedures for refractory atrial tachycardias have
been employed successfully (69-71) . Certainly, with future
understanding and technical developments, wider applica-
tions will result . We have previously ignored the potential
role of surgery in the most common of supraventricular
tachyarrthymias, atrial fibrillation . This rhythm, which
causes 10% of all strokes (-50,000/year) will certainly come
under surgical scrutiny (7 ). Surgical techniques will develop
to nullify both the embolic potential and the hemodynamic
consequences of atrial fibrillation by preserving a normal
sinus mechanism .
Ventricular tachyarrhythmias . Direct surgical techniques
for the therapy of medically refractory ischemic ventricular
tachycardia have been in clinical use for a decade . However,
this cumulative experience would indicate high operative
mortalities as well as high postoperative rates of reinducibil-
ity (73-79). These experiences would suggest that properly
performed procedures to exercise or exclude a focus guided
by proper intraoperative mapping reduces a postoperative
reinducibility (80,81). With the future development of intra-
operative mapping systems that can simultaneously record
endocardial data from multiple sites without opening the
ventricle, many of the current difficulties will be overcome
and results will surely improve (8 ,83) . Great advances in
computer technology will allow the manufacture and wide-
spread availability of such a system at reasonable cost .
Nonetheless, patient selection will need to improve to ex-
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Figure 1 . Proposed placement of the permanent left
ventricular assist pump. The pump is positioned in the
preperitoneal space in the abdomen, fills from the left
Compliance ventricular apex and ejects into the ascending aorta . The
Chamber energy is provided by a battery pack and is transmitted
through the skin by a transcutaneous energy transmis-
sion system (TETS) . The electronic control system,
Infusion port
emergency battery (emer. batt .) pack and air system
(infusion port and compliance chamber) are necessary
components .
dude those patients with concomitant disease or poor left tachycardia surgery will be performed in appropriately se-
ventricular function . With the expected improvement in lected patients, achieving cure, and AIM will be implanted
automatic internal card iodefibrilIators (AICD), ventricular for palliation in the others . The role of additional protection
Figure . Prototype of the permanent left ventricular
assist system that is being developed at The Pennsylva-
nia State University . The miniature blood pump with
Bjork-Shiley valves is seen in the center of the photo-
graph . Currently, this pump is energized by wires cross-
ing the chest wall (right) . Other components include an
infusion port (top, center), a compliance chamber (left)
and a thermistor probe (lower left) . Left ventricular
assist pumps have been used in animal studies for >6
month periods .
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Figure 3. Proposed placement of an electric artificial heart within
the thorax . To obviate the problems of percutaneous tubes, the
design will employ a transcutaneous energy transmission system
with the primary coil positioned with use of a belt . The patient will
carry a case containing chargeable batteries .
of concomitant AICD implantation after directed surgery
will surely be defined more clearly (84) . Additional advances
in the conduct of these direct surgical therapies will combine
excision with laser or cryoablative techniques, or both
(85,86) .
Transplantation
Donor heart availability and preservation . Cardiac trans-
plantation will continue to be an important therapeutic
modality for patients with end-stage heart disease . Because
the profession and the lay public will be better informed
regarding the usefulness of donor organs, fewer potential
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donor organs will be wasted . However, enforced occupa-
tional and vehicular safety rules will further limit the number
of trauma deaths and thus the availability of donor organs .
The need for donor organs will exceed the availability by a
factor of 10 . Because permanent support devices and artifi-
cial hearts will be shelf items, triage will occur with the
younger, better risk patients having the transplant and the
older patient having the mechanical device .
Techniques for long-term (i .e ., > 4 h) preservation of the
heart will allow the transplant to be performed in a more
efficient manner and will allow country-wide and even
worldwide organ sharing (87) . These techniques will also be
helpful in increasing the number of available donor organs .
The idea of using animal hearts to replace the deceased
human heart is not new ; major advances in immunology will
be required and would have major implications throughout
the field of transplantation .
Lung transplantation . Unilateral and bilateral lung trans-
plantation will be useful therapeutic techniques because of a
better understanding of anastomotic techniques and the
availability of improved immunosuppressive therapy (88) .
Improved preservation techniques will allow distant organ
procurement and organ storage and, accordingly, will in-
crease the availability of lungs suitable for transplantation .
The use of combined heart-lung transplantation will seldom
be required .
Organ selection . Immunosuppressive drug programs will
be organ selective, donor antigen specific, and, accordingly,
will minimize systemic side effects such as Cushing's syn-
drome and bulemia. The need for donor organ biopsy to
define rejection and to monitor immunotherapy limits the
organ recipient to living near medical centers and adds to the
medical costs . Better techniques will be identified that will
decrease or eliminate the need for organ biopsy and permit
patient follow-up without necessitating hospitalization . Cur-
rent candidate studies include echocardiography, nuclear
magnetic resonance spectroscopy, detection of characteris-
tics of circulating white cells or detection of changes in
antibody levels in peripheral blood (89) . Clearly, this is a
current topic of great interest and importance .
Mechanical Circulatory Support and the
Artificial Heart
The end result of a variety of forms of heart disease is
irreversible left ventricle muscle damage. No currently
known technique can restore contractile force . Cardiac
transplantation offers the only available hope but is not
readily available ; it is costly and the long-term results are a
compromise . The use of skeletal muscle to replace areas of
cardiac muscle or support devices or the use of blood pumps
powered by such muscle or by conventional power provides
potential alternatives .
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Skeletal muscle cardiomyoplasty . After the development
of techniques to make skeletal muscle fatigue resistant,
many investigations have begun to develop and evaluate
techniques to wrap or incorporate skeletal muscle strips into
the damaged left ventricle (90) . Alternatively, some type of
counterpulsation apparatus or blood pump can be powered
by such a preconditioned muscle (91,9 ). The use of skeletal
muscle to provide augmentation of the cardiac muscle has a
definite advantage over the mechanical cardiac assist de-
vices currently under development in that no external power
source is required, although the energy available through
muscle contraction is limited . Therefore, major circulatory
support by such a biologic system seems unlikely . Accord-
ingly, patients who require a 15% to 0% augmentation in
cardiac output may benefit from some variant of cardiomy-
oplasty, whereas patients who require a greater degree of
support or who require exercise ability will be candidates for
transplantation or an implanted blood pump .
Ventricular assist devices . Within the next several years,
implantable left ventricular assist pumps for permanent
circulatory support will undergo clinical trials (Fig . 1)
(93,94) . These blood pumps will be used in patients who are
not eligible for cardiac transplantation by virtue of age,
contraindication to transplantation (insulin-dependent diabe-
tes, for example) or lack of availability of a donor heart at the
time of need . Permanent left ventricular assist pump system
features include an implantable, valved, pulsatile pump and
a miniature, electrically powered prime mover in the form of
a rotary solenoid or brushless direct current motor (Fig . ) .
The electrical energy required (1 to 18 W) will be provided
by conventional house supply or by a rechargeable battery
pack that can be carried and will be transmitted across the
chest wall by inductive coupling (transformer principle)
techniques, obviating the need for a wire or tube to cross the
chest wall and reducing the risk of infection associated with
JACC Vol . 14, No
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Figure 4 . Prototype of the electric artificial heart . The
two valved ventricles are positioned at the end of the
electric motor-motion translator unit . Also shown is the
percutaneous wire and the air system (compliance
chamber and air port) . A heart of this type has been used
for >7 months in an experimental animal .
percutaneous access sites . Patients with these blood pumps
will require anticoagulant therapy and will have the added
inconvenience of the external electrical source .
The original design features for an implantable ventricular
assist pump incorporated an implantable thermal energy
source (plutonium- 38) and a compact external combustion
(Stirling cycle) engine (95) . However, the high cost of the
plutonium and the risks associated with the radionuclide
(two major nuclear reactor accidents have occurred in the
1980s) have led to a virtual standstill in this design . Alterna-
tively, the major advances in permanent magnets and in the
availability of microprocessors have made the completely
electrical system even more practical .
Implantable artificial heart . An implantable artificial
heart will be available for patients with biventricular failure
in whom a transplant cannot be performed and in those in
whom univentricular support is inappropriate (Fig . 3) . The
artificial heart that will be available at the turn of the century
will have a distinct advantage over the pneumatic devices
used for Dr. Barney Clark (96) . The electrical devices under
development obviate the need for percutaneous pneumatic
power lines and, in place of the bulky pneumatic power unit,
have a highly portable battery pack (Fig . 4) (97,98) . Again
the electrical energy will be transmitted across the skin with
use of wireless techniques . At present, prototype systems
are designed, suitable control techniques are available and
animal implant studies are in progress . One animal has been
supported for 7 months with an artificial heart of this type
(although hard wire electrical transmission was used) (99) .
Although these implanted pumps will be designated as
permanent devices, they will have a definite functional life,
analogous to that of a pacemaker . The first implantable
pumps will have a proved functional life from 1 to years .
Periodic noninvasive parameter checks will indicate impend-
ing device failure (increased power consumption, abnormal
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noise, for example) and the need for device replacement .
Premature failure may also occur . In the patient with the
implanted assist device, such a failure will not be cata-
strophic because the patient's own heart will be capable of
some degree of circulatory support . Although safety circuits
will be included in the implantable artificial hearts, complete
backup systems will not be available because of the limited
space within the chest . However, because the artificial heart
will come to clinical use after the assist device, many of the
premature failure modes will have been studied and elimi-
nated .
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